Market Scenario

The global breast biopsy market is expected to grow significantly during the forecast period (2018–2023).

A biopsy is a small operation performed to remove tissues from an area of concern in the body. Breast biopsy is a procedure that involves testing of small samples of breast tissues for detecting breast cancer. Breast biopsies are conducted using minimal invasive biopsy systems, owing to minimal disfigurement and pain.

There are different types of biopsy procedures depending on the technique, such as core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB) recommended by the doctor based on the location, size, and other characteristics of the breast abnormality.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6288



The increase in the prevalence of breast cancer, especially among women above the age of 35 during menopause (are more susceptible to breast cancer) and growth in the awareness regarding breast cancer screening programs drive the market growth. However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restraints for the market include the high cost of surgical procedures and risks involved in them. Conversely, the emergence of technologically-advanced and minimally invasive breast biopsy devices are expected to provide lucrative opportunities in the untapped market.

Segmentation

The global breast biopsy market has been segmented on the basis of product, technique type, guidance technology, and end-user.

On the basis of product, the market has been classified as biopsy needles, biopsy tables, biopsy wires, guidance systems, and others.

On the basis of technique type, the market is classified into fine needle aspiration biopsy, core needle biopsy, biopsy markers, MRI-guided core needle biopsy, surgical biopsy, wire localization, and sentinel node biopsy. Further, core needle biopsy is divided into stereotactic core needle biopsy, vacuum-assisted biopsy, ultrasound-guided core biopsy, and freehand core-needle biopsy. Surgical biopsy is segmented into incisional biopsy and excisional biopsy.

On the basis of guidance technology, the market is classified into ultrasound-guided, mammography-guided magnetic resonance, CT-guided biopsy, and other image-guided breast biopsy (PET and thermography).

On the basis of end-user, the market is divided into hospitals, ambulatory surgical centers, diagnostic centers, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European breast biopsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The breast biopsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The breast biopsy market in the Middle East and Africa has been segmented into the Middle East and Africa.

Company Profiles

Leica Biosystems
R. Bard Inc.
NuVue Therapeutics
Argon Medical Devices, Inc.
Becton, Dickinson and Company,
Devicor Medical Products Inc.
Hologic Inc.
Argon Medical Devices,
Cook Medical Incorporated
Encapsule Medical Devices LLC.
Johnson & Johnson
Galini SRL
Intact Medical Corporation
Conceptus INC
Karl Storz GmbH & Co. Kg
GE Healthcare
Regional Market Summary

In the breast biopsy market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies and continuous development by companies operating in cancer diagnostics. The global breast biopsy market is largely focused on North America and Europe, which is valued to account for more than 50% of the market share.

The European market is expected to hold the second largest market share as breast cancer is most common in the UK and Belgium. According to the Cancer Research UK in 2015, 55122 new cases of invasive breast cancer were diagnosed.

The market share in the Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities, growing demand for advanced technology, better adoption rate, increasing government initiatives, and rising healthcare expenditure.

The market in the Middle East and Africa is expected to account for the smallest share of the global breast biopsy market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/6288

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

...Continued



Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/6288



About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]